Uniplan Investment Counsel Inc. trimmed its stake in NeoGenomics, Inc. (NASDAQ:NEO) by 11.3% in the 3rd quarter, HoldingsChannel reports. The fund owned 642,538 shares of the medical research company’s stock after selling 82,056 shares during the quarter. Uniplan Investment Counsel Inc.’s holdings in NeoGenomics were worth $9,862,000 as of its most recent SEC filing.
Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. WINTON GROUP Ltd increased its position in NeoGenomics by 23.5% during the 3rd quarter. WINTON GROUP Ltd now owns 25,530 shares of the medical research company’s stock valued at $392,000 after buying an additional 4,866 shares in the last quarter. American International Group Inc. increased its position in NeoGenomics by 15.5% during the 3rd quarter. American International Group Inc. now owns 42,114 shares of the medical research company’s stock valued at $646,000 after buying an additional 5,652 shares in the last quarter. Jennison Associates LLC increased its position in NeoGenomics by 18.7% during the 2nd quarter. Jennison Associates LLC now owns 43,736 shares of the medical research company’s stock valued at $573,000 after buying an additional 6,888 shares in the last quarter. Cornerstone Wealth Management LLC acquired a new position in NeoGenomics during the 2nd quarter valued at about $528,000. Finally, United Services Automobile Association increased its position in NeoGenomics by 2.1% during the 3rd quarter. United Services Automobile Association now owns 398,683 shares of the medical research company’s stock valued at $6,120,000 after buying an additional 8,220 shares in the last quarter. 83.61% of the stock is owned by hedge funds and other institutional investors.
In other news, insider Robert J. Shovlin sold 216,493 shares of the company’s stock in a transaction dated Monday, November 12th. The stock was sold at an average price of $17.00, for a total value of $3,680,381.00. Following the sale, the insider now owns 339,884 shares in the company, valued at $5,778,028. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Lynn A. Tetrault sold 13,000 shares of the company’s stock in a transaction dated Monday, November 19th. The stock was sold at an average price of $16.00, for a total value of $208,000.00. Following the completion of the sale, the director now owns 40,234 shares in the company, valued at approximately $643,744. The disclosure for this sale can be found here. Insiders sold 4,994,643 shares of company stock worth $83,771,998 in the last 90 days. Company insiders own 12.20% of the company’s stock.
NeoGenomics (NASDAQ:NEO) last issued its earnings results on Tuesday, October 30th. The medical research company reported $0.05 EPS for the quarter, topping analysts’ consensus estimates of $0.02 by $0.03. NeoGenomics had a return on equity of 2.63% and a net margin of 1.70%. The firm had revenue of $69.10 million for the quarter, compared to the consensus estimate of $66.13 million. During the same quarter in the prior year, the business earned $0.01 earnings per share. The company’s revenue was up 16.8% compared to the same quarter last year. Research analysts anticipate that NeoGenomics, Inc. will post 0.11 EPS for the current year.
Several research analysts recently issued reports on NEO shares. Craig Hallum upped their target price on NeoGenomics from $17.00 to $22.00 and gave the company a “buy” rating in a research report on Wednesday, October 31st. Leerink Swann started coverage on NeoGenomics in a research report on Tuesday, August 21st. They set an “outperform” rating and a $18.00 target price on the stock. BidaskClub raised NeoGenomics from a “buy” rating to a “strong-buy” rating in a research report on Friday, September 21st. First Analysis set a $16.00 price objective on NeoGenomics and gave the company a “buy” rating in a report on Tuesday, September 18th. Finally, Scotiabank reissued an “average” rating and issued a $24.00 price objective on shares of NeoGenomics in a report on Friday, November 16th. Two investment analysts have rated the stock with a hold rating, nine have assigned a buy rating and two have assigned a strong buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average price target of $20.33.
TRADEMARK VIOLATION WARNING: “Uniplan Investment Counsel Inc. Sells 82,056 Shares of NeoGenomics, Inc. (NEO)” was originally published by Community Financial News and is the property of of Community Financial News. If you are viewing this news story on another domain, it was illegally copied and republished in violation of U.S. and international copyright & trademark laws. The legal version of this news story can be accessed at https://www.com-unik.info/2018/12/04/uniplan-investment-counsel-inc-sells-82056-shares-of-neogenomics-inc-neo.html.
NeoGenomics, Inc, together with its subsidiaries, operates a network of cancer-focused genetic testing laboratories in the United States. It operates through Clinical Services and Pharma Services segments. The company laboratories provide genetic and molecular testing services to hospitals, pathologists, oncologists, urologists, other clinicians and researchers, pharmaceutical firms, and other clinical laboratories.
Featured Article: NASDAQ Stock Market Explained
Want to see what other hedge funds are holding NEO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for NeoGenomics, Inc. (NASDAQ:NEO).
Receive News & Ratings for NeoGenomics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeoGenomics and related companies with MarketBeat.com's FREE daily email newsletter.